These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11896106)

  • 1. Cancer incidence in a population of Jewish women at risk of ovarian cancer.
    Liede A; Karlan BY; Baldwin RL; Platt LD; Kuperstein G; Narod SA
    J Clin Oncol; 2002 Mar; 20(6):1570-7. PubMed ID: 11896106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
    Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
    Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies.
    Antoniou AC; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
    J Med Genet; 2005 Jul; 42(7):602-3. PubMed ID: 15994883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.
    Finkelman BS; Rubinstein WS; Friedman S; Friebel TM; Dubitsky S; Schonberger NS; Shoretz R; Singer CF; Blum JL; Tung N; Olopade OI; Weitzel JN; Lynch HT; Snyder C; Garber JE; Schildkraut J; Daly MB; Isaacs C; Pichert G; Neuhausen SL; Couch FJ; van't Veer L; Eeles R; Bancroft E; Evans DG; Ganz PA; Tomlinson GE; Narod SA; Matloff E; Domchek S; Rebbeck TR
    J Clin Oncol; 2012 Apr; 30(12):1321-8. PubMed ID: 22430266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.
    Lavie O; Narod S; Lejbkowicz F; Dishon S; Goldberg Y; Gemer O; Rennert G
    Ann Oncol; 2011 Apr; 22(4):964-966. PubMed ID: 20924075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
    Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
    Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
    Phelan CM; Kwan E; Jack E; Li S; Morgan C; Aubé J; Hanna D; Narod SA
    Hum Mutat; 2002 Nov; 20(5):352-7. PubMed ID: 12402332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
    Abeliovich D; Kaduri L; Lerer I; Weinberg N; Amir G; Sagi M; Zlotogora J; Heching N; Peretz T
    Am J Hum Genet; 1997 Mar; 60(3):505-14. PubMed ID: 9042909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.
    Hodgson SV; Heap E; Cameron J; Ellis D; Mathew CG; Eeles RA; Solomon E; Lewis CM
    J Med Genet; 1999 May; 36(5):369-73. PubMed ID: 10353781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.
    Robson M; Dabney MK; Rosenthal G; Ludwig S; Seltzer MH; Gilewski T; Haas B; Osborne M; Norton L; Gilbert F; Offit K
    Genet Test; 1997; 1(1):47-51. PubMed ID: 10464625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic.
    Shih HA; Couch FJ; Nathanson KL; Blackwood MA; Rebbeck TR; Armstrong KA; Calzone K; Stopfer J; Seal S; Stratton MR; Weber BL
    J Clin Oncol; 2002 Feb; 20(4):994-9. PubMed ID: 11844822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study.
    Rutter JL; Wacholder S; Chetrit A; Lubin F; Menczer J; Ebbers S; Tucker MA; Struewing JP; Hartge P
    J Natl Cancer Inst; 2003 Jul; 95(14):1072-8. PubMed ID: 12865453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
    Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
    Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening.
    Metcalfe KA; Mian N; Enmore M; Poll A; Llacuachaqui M; Nanda S; Sun P; Hughes KS; Narod SA
    Breast Cancer Res Treat; 2012 Jun; 133(2):735-40. PubMed ID: 22240989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
    Robson M; Levin D; Federici M; Satagopan J; Bogolminy F; Heerdt A; Borgen P; McCormick B; Hudis C; Norton L; Boyd J; Offit K
    J Natl Cancer Inst; 1999 Dec; 91(24):2112-7. PubMed ID: 10601383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
    Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
    Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.